Crinetics Pharmaceuticals, Inc. (CRNX)
CRNX Stock Price Chart
Explore Crinetics Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze CRNX price movements and trends.
CRNX Company Profile
Discover essential business fundamentals and corporate details for Crinetics Pharmaceuticals, Inc. (CRNX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jul 2018
Employees
437.00
Website
https://www.crinetics.comCEO
R. Scott Struthers
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
CRNX Financial Timeline
Browse a chronological timeline of Crinetics Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$1.25.
Earnings released on 7 Aug 2025
EPS came in at -$1.23 falling short of the estimated -$1.13 by -8.85%, while revenue for the quarter reached $1.03M , beating expectations by +81.10%.
Earnings released on 8 May 2025
EPS came in at -$1.04 falling short of the estimated -$0.99 by -5.05%, while revenue for the quarter reached $361.00K , beating expectations by +3.76%.
Earnings released on 27 Feb 2025
EPS came in at -$0.88 surpassing the estimated -$0.92 by +4.35%.
Earnings released on 12 Nov 2024
EPS came in at -$0.96 falling short of the estimated -$0.91 by -5.42%.
Earnings released on 8 Aug 2024
EPS came in at -$0.94 falling short of the estimated -$0.86 by -9.30%, while revenue for the quarter reached $399.00K , missing expectations by -21.76%.
Earnings released on 9 May 2024
EPS came in at -$0.93 falling short of the estimated -$0.84 by -10.71%, while revenue for the quarter reached $640.00K , beating expectations by +146.15%.
Earnings released on 28 Feb 2024
EPS came in at -$0.90 falling short of the estimated -$0.89 by -1.12%.
Earnings released on 7 Nov 2023
EPS came in at -$1.01 falling short of the estimated -$0.89 by -13.48%, while revenue for the quarter reached $346.00K , beating expectations by +82.11%.
Earnings released on 8 Aug 2023
EPS came in at -$0.94 falling short of the estimated -$0.85 by -10.59%, while revenue for the quarter reached $988.00K , beating expectations by +605.71%.
Earnings released on 4 May 2023
EPS came in at -$0.85 falling short of the estimated -$0.82 by -3.66%, while revenue for the quarter reached $2.68M , beating expectations by +325.24%.
Earnings released on 28 Feb 2023
EPS came in at -$0.84 falling short of the estimated -$0.82 by -2.44%, while revenue for the quarter reached $709.00K , beating expectations by +183.60%.
Earnings released on 14 Nov 2022
EPS came in at -$0.78 matching the estimated -$0.78, while revenue for the quarter reached $458.00K , beating expectations by +83.20%.
Earnings released on 12 Aug 2022
EPS came in at -$0.81 falling short of the estimated -$0.62 by -30.65%, while revenue for the quarter reached $439.00K , missing expectations by -26.83%.
Earnings released on 12 May 2022
EPS came in at -$0.73 falling short of the estimated -$0.56 by -30.36%, while revenue for the quarter reached $3.13M , missing expectations by -39.79%.
Earnings released on 30 Mar 2022
EPS came in at -$0.68 falling short of the estimated -$0.57 by -19.30%, while revenue for the quarter reached $1.08M .
Earnings released on 5 Nov 2021
EPS came in at -$0.73 falling short of the estimated -$0.70 by -4.29%.
Earnings released on 10 Aug 2021
EPS came in at -$0.70 falling short of the estimated -$0.60 by -16.67%.
Earnings released on 6 May 2021
EPS came in at -$0.69 falling short of the estimated -$0.65 by -6.15%.
Earnings released on 30 Mar 2021
EPS came in at -$0.66 falling short of the estimated -$0.58 by -13.79%, while revenue for the quarter reached $0.00 .
Earnings released on 6 Nov 2020
EPS came in at -$0.56 falling short of the estimated -$0.52 by -7.69%, while revenue for the quarter reached $0.00 .
CRNX Stock Performance
Access detailed CRNX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.